Intravascular Stents

Global Intravascular Stents Market to Reach US$40.8 Billion by 2030

The global market for Intravascular Stents estimated at US$28.0 Billion in the year 2024, is expected to reach US$40.8 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Drug Eluting Stents, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$26.5 Billion by the end of the analysis period. Growth in the Bare Metal Stents segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.6 Billion While China is Forecast to Grow at 10.2% CAGR

The Intravascular Stents market in the U.S. is estimated at US$7.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.4 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Intravascular Stents Market – Key Trends & Drivers Summarized

Why Are Intravascular Stents Central to the Evolution of Cardiovascular Treatment?

Intravascular stents have become a cornerstone in the management of coronary artery disease (CAD) and peripheral vascular disorders, offering a minimally invasive alternative to surgical interventions. These small mesh-like tubular devices are used to support blood vessels and maintain arterial patency after angioplasty procedures. With cardiovascular diseases remaining the leading cause of death globally, the demand for effective and durable treatment options is driving the expansion of the intravascular stents market. Technological innovation, growing prevalence of lifestyle diseases, and expanded indications in peripheral and neurovascular applications are among the key contributors to market growth.

A significant trend is the transition from bare-metal stents (BMS) to drug-eluting stents (DES) and bioresorbable scaffolds (BRS). DES, which release antiproliferative drugs to prevent restenosis, have largely replaced BMS due to their lower rate of in-stent restenosis and improved long-term outcomes. Bioresorbable stents, although still in early phases of adoption, represent the next generation of vascular intervention technologies by offering temporary scaffolding that dissolves over time. Additionally, advancements in stent delivery systems, coating technologies, and personalized stent sizing are improving procedural success rates and expanding usage across a broader range of vascular conditions.

How Are Innovations in Materials and Design Elevating Clinical Outcomes?

The evolution of intravascular stents is being driven by rapid progress in materials science and device engineering. The use of cobalt-chromium and platinum-chromium alloys in stent construction has enhanced radial strength, visibility under imaging, and flexibility—critical for navigating tortuous vascular anatomies. These materials also allow thinner struts, which reduce vessel trauma and promote faster endothelial healing. In parallel, new-generation DES platforms feature bioabsorbable polymer coatings that degrade after drug release, minimizing long-term inflammation and thrombogenic risk associated with permanent polymers.

In neurovascular and peripheral vascular markets, self-expanding stents made of nitinol (nickel-titanium alloy) are gaining traction due to their superelastic properties and ability to adapt to vessel dynamics. Moreover, the integration of imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) is enhancing stent placement accuracy, ensuring optimal apposition and expansion. Research into nanotechnology-based coatings and gene-eluting stents is also underway, aiming to improve drug delivery efficiency and address limitations like late stent thrombosis. These advances are redefining what’s possible in minimally invasive vascular therapy.

Which Therapeutic Segments and Use Cases Are Driving Adoption?

Coronary artery disease remains the largest segment for intravascular stent use, accounting for the bulk of global procedures. The widespread prevalence of ischemic heart disease, combined with the rising incidence of diabetes, obesity, and hypertension, is fueling procedural volumes in both developed and emerging markets. Intravascular stents are increasingly being used in complex lesions, such as bifurcations, chronic total occlusions, and long diffuse lesions, thanks to more flexible and deliverable stent platforms. These innovations allow interventional cardiologists to expand treatment to high-risk patient groups that were previously unsuitable for stenting.

Beyond coronary applications, peripheral artery disease (PAD) is a growing area of focus, particularly in aging populations. Self-expanding stents are widely used in the femoropopliteal and iliac arteries, providing long-term patency in vessels subject to high biomechanical stress. Neurovascular stents are also seeing increased deployment in the treatment of cerebral aneurysms and ischemic stroke, especially in conjunction with thrombectomy devices. These expanded use cases across coronary, peripheral, and neurovascular domains are not only increasing total addressable market size but also driving demand for specialized stent designs tailored to different vascular environments.

What’s Fueling the Market Growth Across Clinical, Technological, and Regional Dimensions?

The growth in the intravascular stents market is driven by several factors related to clinical demand, innovation pipelines, and expanding healthcare infrastructure. One of the most significant drivers is the aging global population and the associated rise in cardiovascular and peripheral vascular conditions. This demographic shift is creating sustained demand for less invasive, high-efficacy treatment solutions like stents, particularly in outpatient and ambulatory care settings. Concurrently, the global healthcare industry is moving toward value-based care, favoring interventions that minimize hospital stays, reduce complication rates, and improve long-term outcomes—attributes that intravascular stents are well-positioned to deliver.

Another key growth factor is the ongoing R&D investment by medical device companies in next-generation stent platforms. The focus on drug-eluting technology, bioresorbable materials, and AI-integrated stent planning tools is fostering differentiation in an otherwise competitive market. Additionally, the rapid expansion of healthcare access and catheterization labs in Asia-Pacific, Latin America, and the Middle East is contributing to higher procedural volumes. Reimbursement improvements, favorable clinical guidelines, and physician training programs are further supporting adoption in these regions. The convergence of these clinical, technological, and structural drivers is setting the stage for sustained and robust growth in the global intravascular stents market.

SCOPE OF STUDY:

The report analyzes the Intravascular Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Drug Eluting Stents, Bare Metal Stents, Bioabsorbable Stents); Delivery Mode (Self-expanding Stents, Balloon-expandable Stents); Product Type (Coronary Stents, Peripheral Stents, Neurovascular Stents); End-Use (Hospitals & Cardiac Centers, Ambulatory Surgery Centers, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Abbott Laboratories
• Alvimedica
• Asahi Intecc Co., Ltd.
• B. Braun Melsungen AG
• Biosensors International Group
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• C. R. Bard (now part of BD)
• Cardinal Health (Cordis)
• Cook Medical
• Johnson & Johnson
• Medinol Ltd.
• Medtronic plc
• MicroPort Scientific Corporation
• Nipro Corporation
• OrbusNeich Medical
• STENTYS SA
• Terumo Corporation
• Terumo Interventional Systems

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.